We examined the effect of the protein kinase C-selective inhibitor AEB071 (sotrastaurin) on neutrophil functions in vitro. Pre-incubation with AEB071 at concentrations similar to those reached during in vivo therapy significantly reduced cell capacity to migrate toward three different chemo-attractants and to produce superoxide anions (O2) in response to phorbol myristate acetate (PMA) or to iV-formyl-methionyl-leucyl-phenylalanine (fMLP). AEB071 also significantly inhibited the O−2 “overproduction induced by fMLP in neutrophils primed with tumor necrosis factor alpha (TNF-α) or granulocyte/macrophage-colony stimulating factor (GM-CSF). This inhibition was not linked to fMLP-receptor down-regulation since the drug had no effect on either fMLP-receptors or fMLP-induced CD11b membrane expression. When the activity of AEB071 was compared to that of the conventional protein kinase C (PKC) inhibitor Gö6850 (which, like sotrastaurin, inhibits classical and novel PKC isoforms), Gö6976 (an inhibitor of α and β PKC isoforms) and rottlerin (a prevailing δ PKC isoform inhibitor), AEB071 at an equimolar concentration of 3 μM (close to the maximum drug concentration reached in patients treated with AEB071) caused significantly more inhibition on both chemotactic response and superoxide production. These in vitro findings suggest that neutrophils may offer a cellular target for AEB071 activity in vivo.
RoffeyJRosseCLinchMHibbertAMcDonaldNQParkerPJ. Protein kinase C intervention: The state of play 2,4. Curr Opin Cell Biol2009; 21:268–79.
2.
RosseCLinchMKermorgantSCameronAJMBoeckelerKParkerPJ. PKC and the control of localized signal dynamics. Nature Rev Mol Cell Biol2010; 11:103–12.
3.
PfeifhoferCKoflerKGruberTTabriziNGLutzCMalyKLeitgesMBaierG. Protein kinase C theta affects Ca2+ mobilization and NFAT cell activation in primary mouse T cells. J Exp Med2003; 197:1525–35.
4.
PfeifhoferCGruberTLetschkaT. Defective IgG2a/2b class switching in PKC alpha-/- mice. J Immunol2006; 176:6004–11.
5.
SunZArendtCWEllmeierW. PKC-theta is required for TCR-induced NF-kappaB activation in mature but not immature T lymphocytes. Nature2000; 404:402–07.
6.
SuTTGuoBKawakamiY. PKC-beta controls I kappa B kinase lipid raft recruitment and activation in response to BCR signaling. Nat Immunol2002; 3:780–86.
7.
SaijoKMecklenbraukerISantanaALeitgerMSchmedtCTarakhovskyA. Protein kinase C beta controls nuclear factor kappaB activation in B cells through selective regulation of the IkappaB kinase alpha. J Exp Med2002; 195:1647–52.
8.
MecklenbraukerISaijoKZhengNYLeitgesMTarakhovskyA. Protein kinase C delta controls self-antigen-induced B-cell tolerance. Nature2002; 416:860–65.
9.
CastrilloAPenningtonDJOttoFParkerPJOwenMJBoscaL. Protein kinase C epsilon is required for macrophage activation and defense against bacterial infection. J Exp Med2001; 194:1231–42.
10.
AksoyEGoldmanMWillemsF. Protein kinase C epsilon: A new target to control inflammation and immune-mediated disorders. Int J Biochem Cell Biol2004; 36:183–88.
11.
BuddeaKSommererbCBeckercT. Sotrastaurin, a novel small molecule inhibiting protein kinase C: First clinical results in renal-transplant recipients. Am J Transplant2010; 10:571–81.
12.
KilpatrickLEStandageSWLiHRajNRKorchakHMWolfsonMRDeutschmanCS. Protection against sepsis-induced lung injury by selective inhibition of protein kinase. C-d (d-PKC) J Leukoc Biol2011; 89:3–10.
13.
MatzMNaikMMashreghiMFGlanderPNeumayerHHBuddeK. Evaluation of the novel protein kinase C inhibitor sotrastaurin as immunosuppressive therapy after renal transplantation. Expert Opin Drug Metab Toxicol2011; 7:103–13.
14.
SkvaraHDawidMKleynE. The PKC inhibitor AEB071 may be a therapeutic option for psoriasis. J Clin Invest2008; 118:3151–59.
15.
KovarikJMSladeA. Overview of sotrastaurin clinical pharmacokinetics. Drug Monit2010; 32:540–43.
16.
EvenouJPWagnerJZenkeG. The potent protein kinase C-selective inhibitor AEB071 (sotrastaurin) represents a new class of immunosuppressive agents affecting early T-cell activation. J Pharmcol Exp Ther2009; 330:792–01.
17.
MatzMWeberUMashreghiMFLorkowskiCLadhoffJKramerSNeumayerHHBuddeK. Effects of the new immunosuppressive agent AEB071 on human immune cells. Nephrol Dial Transplant2010; 25:2159–67.
18.
ManicassamyS. Sotrastaurin, a protein kinase C inhibitor for the prevention of transplant rejection and treatment of psoriasis. Curr Opin Invest Drugs2009; 10:1225–35.
19.
LodewijkVDekkerLVLeitgesMAltschulerGMistryNMcDermottARoesJSegalAW. Protein kinase C-b contributes to NADPH oxidase activation in neutrophils. Biochem J2000; 347:285–89.
20.
MatronCChakravartiAAllaeysIPoubellePE. PKC-δ controls the fMLF-induced overproduction of superoxide by neutrophils. Free Radic Biol Med2010; 48:207–15.
21.
KilpatrickLESunSLiHVaryTCKorchakHM. Regulation of TNF-induced oxygen radical production in human neutrophils: Role of d-PKC. J Leukoc Biol2010; 87:153–64.
22.
BoyumA. Isolation of mononuclear cells and granulocytes from human blood. Scand J Clin Lab Invest1968; 97:77–89.
23.
BoydenS. The chemotactic effect of mixtures of antibody and antigen on polymorphonuclear leucocytes. J Exp Med1962; 115:453–66.
24.
MetcalfJAGallinJINauseefWMRootRK, eds. Laboratory manual of neutrophil function. Raven Press, New York, 1986; p 96.
25.
SoltoffSP. Rottlerin: An inappropriate and ineffective inhibitor of PKCδ. Trends Pharm Sci2007; 28:453–58.
26.
SegelGBHaltermanMWLichtmanMA. The paradox of the neutrophil's role in tissue injury. J Leukoc Biol2011; 89:359–72.
27.
CummingsRZhaoYJacobyD. Protein kinase C delta mediates lysophosphatidic acid-induced NF-kappaB activation and interleukin-8 secretion in human bronchial epithelial cells. J Biol Chem2004; 279:41085–94.
28.
RahmanAAnwarKNUddinSXuNYeRDPlataniasLCMalikAB. Protein kinase C-delta regulates thrombin-induced ICAM-1 gene expression in endothelial cells via activation of p38 mitogen-activated protein kinase. Mol Cell Biol2011; 21:5554–65.
29.
WooCHLimJHKimJH. VCAM-1 upregulation via PKCdelta-p38 kinase-linked cascade mediates the TNF-alpha-induced leukocyte adhesion and emigration in the lung airway epithelium. Am J Physiol Lung Cell Mol Physiol2005; 288:L307–L316.
30.
KruegerJGBowcockA. Psoriasis pathophysiology: Current concepts of pathogenesis. Ann Rheum Dis2005; 64:30–36.
31.
SmithCHAnsteyAVBarkerJN. British Association of Dermatologists: Guidelines for use of biological interventions in psoriasis. Br J Dermatol2005; 153:486–97.
32.
SterryWBarkerJBoehnckeWH. Biological therapies in the systemic management of psoriasis: International Consensus Conference. Br J Dermatol2004; 151(S):3–17.
33.
SchönMDenzerDKubitzaRCRuzickaTSchönMP. Critical role of neutrophils for the generation of psoriasiform skin lesions in flaky skin mice. J Invest Dermatol2000; 114:976–83.
34.
TeruiTOzawaMTagamiH. Role of neutrophils in induction of acute inflammation in T-cell-mediated immune dermatosis, psoriasis: A neutrophil-associated inflammation-boosting loop. Exp Dermatol2000; 9:1–10.
